# US 2024/0199688 A1 · Methods for reducing lipase activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199688 A1
- Document ID: US20240199688A1
- Status: Published application
- Kind: A1
- Application number: 18/310,921
- Filed: 2023-05-02
- Published: 2024-06-20
- Earliest claimed: 2022-05-02
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Xiaolin Tang; Leonid Breydo; John Mattila
- Web page: https://patentgrep.com/patent/US20240199688A1

## CPC

- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 1/16: by chromatography
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C07K 1/18: Ion-exchange chromatography
- C07K 1/36: by a combination of two or more processes of different types
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-4 receptor alpha (hIL-4Rα) are provided. The formulations may contain, in addition to an anti-IL-4Rα antibody, one or more buffers, at least one amino acid, at least one sugar, and a surfactant comprising a polysorbate, polyethylene glycol or a poloxamer. Methods for producing pharmaceutical formulations with reduced lipase activity are also provided, which may include subjecting a drug substance to anion exchange chromatography in acidic conditions, agitation stress, heat stress, and additional ion exchange or size exclusion chromatography. In one aspect, the pharmaceutical formulations do not have appreciable subvisible particle formation in the presence of lipase, and exhibit a substantial degree of antibody stability during storage and after being subjected to thermal and other physical stresses.

## Claims

### Claim 1

A method for producing a pharmaceutical composition with reduced lipase activity, comprising:
(a) subjecting a sample including a protein of interest and a lipase to stress conditions to form a sample with inactivated lipase; and
(b) formulating said sample with inactivated lipase to produce a pharmaceutical composition with reduced lipase activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein said protein of interest is an antibody, an antibody-derived protein, an antibody fragment, a monoclonal antibody, a bispecific antibody, a fusion protein, an antibody-drug conjugate, or a therapeutic protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein said formulating step comprises adding a fatty acid ester to said sample, wherein said fatty acid ester is polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80.

### Claim 4 (depends on 3)

The method of claim 3, wherein said fatty acid ester is polysorbate 80 and a concentration of oleic acid esters in said polysorbate 80 is at least 80%.

### Claim 5 (depends on 4)

The method of claim 4, wherein a concentration of oleic acid esters in said polysorbate 80 is at least 98% or at least 99%.

### Claim 6 (depends on 1)

The method of claim 1, wherein said stress conditions include agitation stress and/or heat stress.

### Claim 7 (depends on 6)

The method of claim 6, wherein said agitation stress comprises shaking said sample at from 50 to 500 rpm, from 200 to 300 rpm, about 50 rpm, about 75 rpm, about 100 rpm, about 125 rpm, about 150 rpm, about 200 rpm, about 225 rpm, about 250 rpm, about 275 rpm, about 300 rpm, about 325 rpm, about 350 rpm, about 375 rpm, about 400 rpm, about 425 rpm, about 450 rpm, about 475 rpm, or about 500 rpm.

### Claim 8 (depends on 6)

The method of claim 6, wherein said agitation stress comprises shaking said sample for from 1 to 96 hours, from 24 to 48 hours, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 12 hours, about 18 hours, about 24 hours, about 30 hours, about 36 hours, about 42 hours, about 48 hours, about 60 hours, about 72 hours, about 84 hours, or about 96 hours.

### Claim 9 (depends on 6)

The method of claim 6, wherein said heat stress comprises storing said sample at from about 30° ° C. to about 60° C., from about 35° ° C. to about 55° C., from about 40° ° C. to about 50° C., from about 44° C. to about 46° ° C., about 30° C., about 35° C., about 40° C., about 45° C., about 50° C., about 55° C., or about 60° C.

### Claim 10 (depends on 9)

The method of claim 9, wherein said storage is from 1 day to 6 months, from 3 days to 3 months, from 1 week to 2 months, from 0.5 months to 1 month, about 1 day, about 2 days, about 3 days, about 1 week, about 2 weeks, about 0.5 months, about 3 weeks, about 4 weeks, about 1 month, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 3 months, about 3.5 months, about 4 months, about 4.5 months, about 5 months, about 5.5 months, or about 6 months.

### Claim 11 (depends on 1)

The method of claim 1, further comprising subjecting said sample with inactivated lipase to filtration, enrichment, or chromatographic separation to remove high molecular weight (HMW) species prior to step (b).

### Claim 12 (depends on 11)

The method of claim 11, wherein said chromatographic separation comprises cation exchange chromatography.

### Claim 13 (depends on 11)

The method of claim 11, wherein said chromatographic separation comprises size exclusion chromatography.

### Claim 14 (depends on 1)

The method of claim 1, wherein said formulating step comprises adding excipients to said sample.

### Claim 15 (depends on 1)

The method of claim 1, wherein said sample is a drug substance.

### Claim 16

A method for producing a pharmaceutical composition with reduced lipase activity, comprising:
(a) subjecting a drug substance including a protein of interest and a lipase to heat stress to form a drug substance with inactivated lipase;
(b) subjecting said drug substance with inactivated lipase to cation exchange chromatography to form a HMW-depleted drug substance; and
(c) formulating said HMW-depleted drug substance to produce a pharmaceutical composition with reduced lipase activity.

### Claim 17 (depends on 16)

The method of claim 16, wherein said protein of interest is a monoclonal antibody.

### Claim 18 (depends on 16)

The method of claim 16, wherein said formulating step comprises adding polysorbate 20 or polysorbate 80.

### Claim 19 (depends on 16)

The method of claim 16, wherein said heat stress comprises storing said sample at from about 45° ° C. to about 50° C.

### Claim 20 (depends on 19)

The method of claim 19, wherein said storage is from about 0.5 months to about 2 months.
